Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of rAHF-PFM in Hemophilia A Surgery
NCT00157105Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2001
- Primary completion
- Aug 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Takeda. Primary endpoint: Percent of participants experiencing treatment-related adverse experiences at 3.5 years. Started Feb 2001; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00157105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157105.